Maze Therapeutics, Inc. MAZE
32.43 USD +1.23 (+3.94%)
Regular-session close
32.46 +0.03 +0.09%
After hours · Nov 19, 7:43 PM ET
30.69 Day range 32.74
21.95 52-week range 53.65
- YTD
- -21.72%
- 1 year
- -8.75%
News
seekingalpha.com Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It Maze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially…benzinga.com JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51 JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.
benzinga.com Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49 Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.
benzinga.com Maze Therapeutics Q3 EPS $(0.79) Misses $(0.77) Estimate Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 19.7 percent decrease over losses of…
globenewswire.com Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027
zacks.com Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is…
globenewswire.com Maze Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for…
zacks.com What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is…
247wallst.com Here Are Monday’s Top Wall Street Analyst Research Calls: Ameriprise Financial, Boyd Gaming, CoreWeave, Datadog, Intel, JetBlue Airways, PayPal Holdings, Pinterest, Whirlpool, and More Wall Street analysts delivered a dramatic split verdict Monday, slashing targets on financial and consumer names while placing bold bullish bets on AI infrastructure and cloud players. Find out which…benzinga.com Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75 Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
defenseworld.net Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysis Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Maze Therapeutics (NASDAQ: MAZE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
defenseworld.net Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK) Maze Therapeutics (NASDAQ: MAZE - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
globenewswire.com Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research…
marketbeat.com 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been…
defenseworld.net Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40 Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. One…
defenseworld.net Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.5% – Still a Buy? Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report)'s stock price shot up 4.5% on Monday. The company traded as high as $26.91 and last traded at $27.2110. Approximately 354,721 shares traded…
defenseworld.net Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Time to Buy? Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report)'s share price gapped up prior to trading on Tuesday. The stock had previously closed at $22.39, but opened at $24.52. Maze Therapeutics shares…
fool.com Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the…
seekingalpha.com Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
defenseworld.net Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 10.2% during the undefined quarter, according to the company in its most recent disclosure with…
globenewswire.com Maze Therapeutics to Participate in Three Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for…
defenseworld.net BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
defenseworld.net Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional…
